China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
137 hedge funds and large institutions have $2.02B invested in China Biologic Products Holdings, Inc. in 2017 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 49 reducing their positions, and 26 closing their positions.
341% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $2.37M
1% less capital invested
Capital invested by funds: $2.04B → $2.02B (-$15.7M)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
4% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 49
4% less funds holding
Funds holding: 143 → 137 (-6)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$141M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$43.4M |
| 3 |
HIM
Hermes Investment Management
London Uk,
United Kingdom
|
+$32.3M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$29.2M |
| 5 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$28.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$104M |
| 2 |
ACM
Ariose Capital Management
Central, Hong Kong,
Hong Kong
|
-$25.7M |
| 3 |
Ninety One (UK)
London,
United Kingdom
|
-$24.4M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$15.8M |
| 5 |
DKCM
Davidson Kempner Capital Management
New York
|
-$9.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
151
TFS Capital
West Chester,
Pennsylvania
| – | -$889K | -8,267 | Closed |
|
|
MCM
152
McKinley Capital Management
Anchorage,
Alaska
| – | -$666K | -6,190 | Closed |
|
153
Jane Street
New York
| – | -$644K | -5,994 | Closed |
|
|
TI
154
Trexquant Investment
Stamford,
Connecticut
| – | -$462K | -4,300 | Closed |
|
|
NA
155
Navellier & Associates
Reno,
Nevada
| – | -$369K | -3,430 | Closed |
|
|
OAM
156
Origin Asset Management
London,
United Kingdom
| – | -$333K | -3,100 | Closed |
|
157
Simplex Trading
Chicago,
Illinois
| – | -$316K | -2,956 | Closed |
|
|
RJA
158
Raymond James & Associates
St Petersburg,
Florida
| – | -$303K | -2,818 | Closed |
|
159
Citadel Advisors
Miami,
Florida
| – | -$219K | -2,045 | Closed |
|
|
AAM
160
Advisors Asset Management
Monument,
Colorado
| – | -$146K | -1,359 | Closed |
|
161
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$47K | -432 | Closed |
|
|
TRCT
162
Tower Research Capital (TRC)
New York
| – | -$38K | -357 | Closed |
|
|
PCM
163
Penserra Capital Management
Orinda,
California
| – | -$28K | -268 | Closed |
|
CBPO Hedge Fund Activity: Q1 2017 in Review
137 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q1 2017, worth a combined $2.02B — down 0.77% from $2.04B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CBPO and 25 opened new positions — a net loss of 1 holder — while 49 trimmed existing stakes and 47 added.
The largest buyer was BlackRock, adding an estimated $141M. The largest seller was Capital World Investors, cutting an estimated $104M.
- 137 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q1 2017, down from 143 in Q4 2016.
- Funds reported $2.02B of China Biologic Products Holdings, Inc. stock for Q1 2017, down 0.77% quarter-over-quarter.
- 25 funds opened new China Biologic Products Holdings, Inc. positions in Q1 2017 and 26 closed out, a net change of -1 holder.
- The largest China Biologic Products Holdings, Inc. buyer in Q1 2017 was BlackRock, an estimated $141M added.
- The largest China Biologic Products Holdings, Inc. seller in Q1 2017 was Capital World Investors, an estimated $104M sold.
Based on aggregated 13F filings for Q1 2017.